<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945477</url>
  </required_header>
  <id_info>
    <org_study_id>ILCC #1</org_study_id>
    <nct_id>NCT00945477</nct_id>
  </id_info>
  <brief_title>Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade</brief_title>
  <official_title>A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Illinois CancerCare, P.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Illinois CancerCare, P.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A growing body of literature supports the role of angiogenesis in the development and spread&#xD;
      of a variety of human cancers including prostate cancer.&#xD;
&#xD;
        -  Vascular endothelial growth factor (VEGF) expression is low in normal prostate tissue,&#xD;
           but markedly increased in tumor tissues, and has a positive association with tumor stage&#xD;
           and grade&#xD;
&#xD;
        -  Plasma VEGF levels are significantly elevated in patients with hormone refractory&#xD;
           prostate cancer (HRPC) compared to those patients with localized disease and have been&#xD;
           associated with disease progression in other cancer patient population.&#xD;
&#xD;
        -  The Cancer and Leukemic Group-B demonstrated that VEGF levels correlate with survival.&#xD;
&#xD;
      Pazopanib is a potent multi-target receptor tyrosine kinase inhibitor of vascular endothelial&#xD;
      growth factor receptors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VEGF expression is low in all normal prostate tissue, but markedly increased in tumor tissue,&#xD;
      and has a positive association with MVD (micro vessel density) tumor stage, grade, and&#xD;
      disease-specific survival in patients with prostate cancer. VEGF is known to be under the&#xD;
      influence of HIF-1α, which is also up-regulated in the majority of prostate cancer tissue. It&#xD;
      has been shown that complete androgen blockade down-regulates VEGF expression via the HIF-1α&#xD;
      pathway with concomitant up-regulation of thrombospondin and induction of endothelial cell&#xD;
      apoptosis. The VEGF pathway appears to be the dominant vascular formation pathway in prostate&#xD;
      cancer with bFGF having a lesser role.&#xD;
&#xD;
      Pazopanib , a hydrochloride salt, is a small molecule inhibitor of several tyrosine kinases,&#xD;
      ie: VEGF 1, 2, 3, c-KIT and platelet-derived growth factor receptors. The broad blockade of&#xD;
      the VEGF receptors should interfere with the VEGF/VEGF-receptor pathway, and have an impact&#xD;
      on cell growth.&#xD;
&#xD;
      According to the NCCN guidelines , first line therapy for metastatic prostate cancer is&#xD;
      considered total androgen blockade, either utilizing orchiectomy and/or LH/RH agonists plus&#xD;
      Casodex.&#xD;
&#xD;
      Second line therapy would depend on the patient's response to first line therapy, urgency of&#xD;
      a response, and the location of metastatic disease.&#xD;
&#xD;
      Pazopanib has been explored in several settings. It has recently been looked at with&#xD;
      Bicalutamide in hormone refractory prostate cancer. The second study was with earlier&#xD;
      disease, i.e. D-0 relapse androgen-sensitive patients. The University of Chicago has a study&#xD;
      looking at the sub-population of prostate cancer patients that have a &quot;chemical relapse&quot; in&#xD;
      which patients are given one shot of Lupron, and if the PSA is adequately suppressed, the&#xD;
      patients are randomized between pazopanib and placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Response rate defined as 50% decrease in the Prostate Specific Antigen (PSA) level at week 12 compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Adverse Events, Grades 1-5 Using NCI-CTCAE v 3.0</measure>
    <time_frame>0-12 weeks</time_frame>
    <description>Safety was evaluated by documentation of Adverse Events (AEs), by assessment of clinical laboratory findings, and by physicial examination, including measurement of vital signs and weight in all eleven subjects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Advanced prostate cancer, treatment, pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pazopanib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib (GW786034)</intervention_name>
    <description>Pazopanib 800 mg daily x 12 weeks</description>
    <arm_group_label>Advanced prostate cancer, treatment, pazopanib</arm_group_label>
    <other_name>Pazopanib monohydrochloride salt GW786034</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of adenocarcinoma of the prostate histology, currently on total androgen&#xD;
             blockage with a bicalutamide.&#xD;
&#xD;
          2. Subjects must provide written informed consent prior to administration of pazopanib or&#xD;
             the performance of any study-specific procedures or assessments, and must be willing&#xD;
             to comply with treatment and follow up. Procedures conducted as part of the subject's&#xD;
             routine clinical management (e.g., blood count, imaging study) and obtained prior to&#xD;
             signing of informed consent may be utilized for screening or baseline purposes&#xD;
             provided these procedures are conducted as specified in the protocol. Note: It is not&#xD;
             necessary that informed consent be obtained within the protocol-specified screening&#xD;
             window.&#xD;
&#xD;
          3. Received no prior second line hormone therapy or any chemotherapy. No prior&#xD;
             bevacizumab, mTOR inhibitor, sunitinib, sorafenib or other VEGF TKI) for advanced or&#xD;
             metastatic prostate cancer.&#xD;
&#xD;
          4. Must have metastatic diagnosis, meaning disease beyond the prostate gland.&#xD;
&#xD;
          5. A progressing PSA of ≥ 3, the PSA will be measured in ≥ 14 days.&#xD;
&#xD;
          6. KPS of ≥ 70&#xD;
&#xD;
          7. Age ≥ 18 years old&#xD;
&#xD;
          8. Adequate organ system functions:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 X 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Platelets ≥ 100 X 109/L&#xD;
&#xD;
               -  International normalized ratio (INR) ≤ 1.2 X upper limit of normal (ULN)&#xD;
&#xD;
               -  Partial thromboplastin time (PTT) ≤ 1.2 X ULN&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 X ULN&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 X ULN&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
               -  Urine Protein to Creatinine Ratio (UPC)2 &lt; 1&#xD;
&#xD;
               -  Total serum calcium concentration &lt; 12.0mg/dL&#xD;
&#xD;
                    -  Subjects may not have had a transfusion within 7 days of screening&#xD;
                       assessment.&#xD;
&#xD;
                    -  If UPC ≥ 1, then a 24-hour urine protein must be assessed. Subjects must&#xD;
                       have a 24-hour urine protein value &lt; 1 g to be eligible.&#xD;
&#xD;
          9. Left ventricular ejection fraction (LVEF) ≥ 55% as assessed by echocardiography or&#xD;
             multigated acquisition (MUGA) scan. The same modality used at baseline must be applied&#xD;
             for subsequent evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the following criteria must not be enrolled in the study:&#xD;
&#xD;
          1. History of another malignancy.&#xD;
&#xD;
             Note: Subjects who have had another malignancy and have been disease-free for 3 years,&#xD;
             or subjects with a history of completely resected non-melanomatous skin carcinoma or&#xD;
             successfully treated in situ carcinoma are eligible.&#xD;
&#xD;
          2. History or clinical evidence of central nervous system (CNS) metastases.&#xD;
&#xD;
             Note: Subjects who have previously-treated CNS metastases (surgery ± radiotherapy,&#xD;
             radiosurgery, or gamma knife) and meet all 3 of the following criteria are eligible:&#xD;
&#xD;
               -  Are asymptomatic and,&#xD;
&#xD;
               -  Have had no evidence of active CNS metastases for ≥ 6 months prior to enrollment&#xD;
                  and,&#xD;
&#xD;
               -  Have no requirement for steroids or enzyme-inducing anticonvulsants (EIAC).&#xD;
&#xD;
          3. Clinically significant gastrointestinal abnormalities including, but not limited to:&#xD;
&#xD;
               -  Malabsorption syndrome,&#xD;
&#xD;
               -  Major resection of the stomach or small bowel that could affect the absorption of&#xD;
                  study drug,&#xD;
&#xD;
               -  Active peptic ulcer disease,&#xD;
&#xD;
               -  Inflammatory bowel disease,&#xD;
&#xD;
               -  Ulcerative colitis, or other gastrointestinal conditions with increased risk of&#xD;
                  perforation,&#xD;
&#xD;
               -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal&#xD;
                  abscess within 28 days prior to beginning study treatment.&#xD;
&#xD;
          4. Presence of uncontrolled infection.&#xD;
&#xD;
          5. Prolongation of corrected QT interval (QTc) &gt; 480 milliseconds (msecs).&#xD;
&#xD;
          6. History of any one or more of the following cardiovascular conditions within the past&#xD;
             12 months:&#xD;
&#xD;
               -  Cardiac angioplasty or stenting,&#xD;
&#xD;
               -  Myocardial infarction,&#xD;
&#xD;
               -  Unstable angina,&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease,&#xD;
&#xD;
               -  Class III or IV congestive heart failure, as defined by the New York Heart&#xD;
                  Association (NYHA).&#xD;
&#xD;
          7. History of cerebrovascular accident (CVA) including transient ischemic attack (TIA).&#xD;
&#xD;
          8. History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the&#xD;
             past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic&#xD;
             anticoagulating agents for at least 6 weeks are eligible.&#xD;
&#xD;
          9. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥150mmHg&#xD;
             or diastolic blood pressure (DBP) of ≥ 90 mmHg].&#xD;
&#xD;
             Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to&#xD;
             study entry. Blood pressure must be re-assessed on two occasions that are separated by&#xD;
             a minimum of 24 hours. The mean SBP/DBP values from each blood pressure assessment&#xD;
             must be &lt; 150/90mmHg in order for a subject to be eligible for the study. See Section&#xD;
             6.3.2 for instruction on blood pressure measurement and obtaining mean blood pressure&#xD;
             values.&#xD;
&#xD;
         10. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or&#xD;
             presence of any non-healing wound, fracture, or ulcer.&#xD;
&#xD;
         11. Evidence of active bleeding or bleeding diathesis&#xD;
&#xD;
         12. Hemoptysis within 6 weeks of first dose of study drug.&#xD;
&#xD;
         13. Any serious and/or unstable pre-existing medical, psychiatric, or other conditions&#xD;
             that could interfere with subject's safety, obtaining informed consent or compliance&#xD;
             to the study.&#xD;
&#xD;
         14. Prohibited medications within 28 days unless the half-life of the medication is longer&#xD;
             than 28 days, will not be permitted.&#xD;
&#xD;
         15. Use of an investigational agent, including an investigational anti-cancer agent,&#xD;
             within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
         16. Prior use of an investigational or licensed drug that targets VEGF or VEGF receptors&#xD;
             (e.g., bevacizumab, sunitinib, sorafenib, etc), or are mTOR inhibitors (eg.&#xD;
             temsirolimus, everolimus, etc).&#xD;
&#xD;
         17. Is now undergoing and/or has undergone in the last 4 weeks immediately prior to first&#xD;
             dose of study drug, (surgery, tumor embolization, chemotherapy, radiation therapy,&#xD;
             immunotherapy, or biological therapy)&#xD;
&#xD;
         18. Any ongoing toxicity from prior anti-cancer therapy that is &gt; Grade 1 and/or that is&#xD;
             progressing in severity.&#xD;
&#xD;
         19. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to pazopanib.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Illinois CancerCare</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare</name>
      <address>
        <city>Pekin</city>
        <state>Illinois</state>
        <zip>61554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <results_first_submitted>October 24, 2012</results_first_submitted>
  <results_first_submitted_qc>October 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2013</results_first_posted>
  <last_update_submitted>October 25, 2013</last_update_submitted>
  <last_update_submitted_qc>October 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Illinois CancerCare, P.C.</investigator_affiliation>
    <investigator_full_name>James Knost</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Male patients were enrolled from 7/17/2009 through 10/9/2012. All patients were from our practice and screened from our database.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Advanced Prostate Cancer, Treatment, Pazopanib</title>
          <description>Pazopanib&#xD;
Pazopanib (GW786034) : Pazopanib 800 mg daily x 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Advanced Prostate Cancer, Treatment, Pazopanib</title>
          <description>Pazopanib&#xD;
Pazopanib (GW786034) : Pazopanib 800 mg daily x 12 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.5" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate at 12 Weeks</title>
        <description>Response rate defined as 50% decrease in the Prostate Specific Antigen (PSA) level at week 12 compared to baseline</description>
        <time_frame>12 weeks</time_frame>
        <population>Five subjects completed the 12 week treatment requirement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib 800mg Daily by Mouth</title>
            <description>Response rate at 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate at 12 Weeks</title>
          <description>Response rate defined as 50% decrease in the Prostate Specific Antigen (PSA) level at week 12 compared to baseline</description>
          <population>Five subjects completed the 12 week treatment requirement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Adverse Events, Grades 1-5 Using NCI-CTCAE v 3.0</title>
        <description>Safety was evaluated by documentation of Adverse Events (AEs), by assessment of clinical laboratory findings, and by physicial examination, including measurement of vital signs and weight in all eleven subjects.</description>
        <time_frame>0-12 weeks</time_frame>
        <population>The adverse events for all participants enrolled were evaluated by documentation of Adverse Events (AEs)Grades 1-5 using NCI-CTCAE v 3.0</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Adverse Events 800mg Pazopanib</title>
            <description>Adverse events for all participants, all grades</description>
          </group>
        </group_list>
        <measure>
          <title>Number Adverse Events, Grades 1-5 Using NCI-CTCAE v 3.0</title>
          <description>Safety was evaluated by documentation of Adverse Events (AEs), by assessment of clinical laboratory findings, and by physicial examination, including measurement of vital signs and weight in all eleven subjects.</description>
          <population>The adverse events for all participants enrolled were evaluated by documentation of Adverse Events (AEs)Grades 1-5 using NCI-CTCAE v 3.0</population>
          <units>Adverse events Grade 1-5</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0-12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pazopanib 800mg Daily by Mouth</title>
          <description>Response rate at 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>CTC AE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>AST (SGOT)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sodium-serum, low</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because of slow enrollment, the study was terminated. The study planned enrollment of 34 subjects, 11 were enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James Knost, M.D.</name_or_title>
      <organization>Illinois CancerCare, P.C.</organization>
      <phone>309-243-3000</phone>
      <email>jknost@illinoiscancercare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

